mosaiques diagnostics and therapeutics AG
Chronic diseases are widespread in the U.S. and pose a significant health challenge
Cardiovascular diseases (CVD) include a range of conditions that affect the heart and blood vessels, such as coronary artery disease, heart failure, and high blood pressure. They are the leading cause of death in the U.S.
Prevalence: About 48% people (approximately 122 million people) in the U.S. suffer from some form of cardiovascular disease.
Costs: Treating cardiovascular diseases is highly expensive, contributing to hundreds of billions of dollars annually in direct medical expenses and lost productivity.
Chronic kidney disease (CKD) impairs kidney function, and in severe cases, it can lead to kidney failure, requiring dialysis or a kidney transplant.
Prevalence: Around 15% people (about 37 million people) have CKD. However, many are unaware of their condition, as symptoms often do not appear in the early stages.
Dialysis and Transplantation: For individuals with kidney failure (end-stage renal disease, ESRD), dialysis is essential for survival, and a kidney transplant is considered the most effective long-term treatment.
Costs: The treatment of CKD, particularly ESRD, is extremely costly, with dialysis patients facing annual costs exceeding $90,000 per patient.
Comorbidities: Cardiovascular and kidney diseases frequently co-occur. For instance, people with high blood pressure or diabetes are at increased risk for both heart and kidney diseases. Both disease categories underscore the need for preventive care and early detection to reduce the burden on individuals and the healthcare system.
Mosaiques and peer-group
The collection and identification of the specific disease proteome associated with the patho-physiology is the decisive and most significant difference to all other methods. This approach is applicable for any disease state. In addition, it is the clinical studies that demonstrate the clinical utility of the approved proteomic biomarkers that significantly differentiate mosaiques from all other approaches to proteome detection.
For many years, the financial market has been searching for companies with the possibility of individualized disease detection and personalized therapy determinations. The companies present on the market usually cannot present qualified, evidence-based clinical studies with their method, corresponding database, and registration for approval as in-vitro diagnostics.
olink - was able to achieve a valuation of 3.1 billion dollars in the merger with Thermo Fisher Scientific for its B2B business in antibody-based proteome chips alone. Other companies in this sector achieved even higher valuations over the last 10 years, without demonstrating proteomic analysis quality and evidence of benefit in clinical applications.
Mosaiques is the only proteomic company worldwide that
- Decodes the proteomic mechanism of action of chronic diseases,
- has approved and markets diagnostic tests with high accuracy for early molecular detection (8 tests)
- has significant study evidence and expertise,
- has a unique proteome database and
- presents an innovative proteome based approach to drug development where the proprietary database and knowledge of the proteins significant changes is coordinated with the globally available, accessible knowledge of active substances in order to identify qualified drug candidates. These are tested in appropriate model systems with known similarity to the disease-specific human proteome. This approach has been discussed with EMA. The FDA issued a letter of support for the proteome test for chronic kidney disease in 2016.
Mosaiques diagnostics and therapeutics AG is about to roll out its diagnostic service worldwide!
The risky, thorny path of gaining scientific acceptance and demmonstrate benefit in complex clinical trials, some of which for a period of eight years, has already been successfully completed. This cardinal risk for every investor has been successfully completed!
Now it is a matter of complex and rapid market development!
We are looking for solid partners who:
- have worldwide contacts to build a distribution network for diagnostics in the leading countries - USA - Europe - Asia (excluding China),
- can drive expansion in drug development, including through collaborations, and
- have expertise in an IPO, which is planned in the USA in the next few years.
We are looking for one to three solid investment companies or strategic partnerships.
Website:
B2B:
B2C: